For Healthcare Professionals

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

clipboard-pencil

About the study

The primary objectives of the study are: To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: To characterize real-world utilization of DUPIXENT® for patients with CRSwNP To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Key Inclusion Criteria:

  1. All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
  2. Willing and able to comply with clinic visits and study-related procedures as per protocol
  3. Provide informed consent signed by study patient or legally acceptable representative
  4. Able to understand and complete study-related questionnaires as per protocol

EXCLUSION CRITERIA

Key Exclusion Criteria:

  1. Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
  2. Any previous treatment with DUPIXENT® for any condition
  3. Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol
  4. Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Chronic Rhinosinusitis With Nasal Polyposis

Age (in years)

18+

Participants needed

1000

Est. Completion Date

Aug 17, 2026

Treatment type

Observational


Sponsor

Regeneron Pharmaceuticals

ClinicalTrials.gov identifier

NCT04959448

Study number

R668-cSNP-2072

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.